These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 31196658

  • 1. Urinary osmolality in patients with polycystic kidney disease: Measured or calculated?
    Borrego Utiel FJ, Camacho Reina MV, Moriana Domínguez C, Merino García E.
    Nefrologia (Engl Ed); 2020; 40(2):202-204. PubMed ID: 31196658
    [No Abstract] [Full Text] [Related]

  • 2. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G, Asselin-Thompstone L, Mac-Way F, René de Cotret P, Lacroix C, Desmeules S, Agharazii M.
    Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201
    [Abstract] [Full Text] [Related]

  • 3. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
    Bargagli M, Dhayat NA, Anderegg M, Semmo M, Huynh-Do U, Vogt B, Ferraro PM, Fuster DG.
    Clin J Am Soc Nephrol; 2020 Jul 01; 15(7):1007-1014. PubMed ID: 32527945
    [Abstract] [Full Text] [Related]

  • 4. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
    Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.
    J Am Soc Nephrol; 2017 May 01; 28(5):1592-1602. PubMed ID: 27920153
    [Abstract] [Full Text] [Related]

  • 5. Identifying the main predictors of urine output in autosomal-dominant polycystic kidney disease (ADPKD) patients taking tolvaptan.
    Utiel FJB, García AIM, Moyano AP, Oporto FR, García EM, de la Rosa RE.
    Int Urol Nephrol; 2023 Oct 01; 55(10):2629-2637. PubMed ID: 36952108
    [Abstract] [Full Text] [Related]

  • 6. Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis.
    Ivaturi V, Gobburu J, Leslie B, Wang X, Jadhav P.
    Kidney360; 2024 Jul 01; 5(7):996-1001. PubMed ID: 38857379
    [Abstract] [Full Text] [Related]

  • 7. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.
    Am J Kidney Dis; 2015 Jun 01; 65(6):833-41. PubMed ID: 25600953
    [Abstract] [Full Text] [Related]

  • 8. Immediate drop of urine osmolality upon tolvaptan initiation predicts impact on renal prognosis in patients with ADPKD.
    Akihisa T, Kataoka H, Makabe S, Manabe S, Yoshida R, Ushio Y, Sato M, Yajima A, Hanafusa N, Tsuchiya K, Nitta K, Hoshino J, Mochizuki T.
    Nephrol Dial Transplant; 2024 May 31; 39(6):1008-1015. PubMed ID: 37935473
    [Abstract] [Full Text] [Related]

  • 9. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT.
    Am J Kidney Dis; 2019 Mar 31; 73(3):354-362. PubMed ID: 30578153
    [Abstract] [Full Text] [Related]

  • 10. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
    Minami S, Hamano T, Iwatani H, Mizui M, Kimura Y, Isaka Y.
    Clin Exp Nephrol; 2018 Jun 31; 22(3):550-561. PubMed ID: 29052786
    [Abstract] [Full Text] [Related]

  • 11. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial.
    Uchiyama K, Kitayama C, Yanai A, Ishibashi Y.
    Sci Rep; 2021 Sep 03; 11(1):17666. PubMed ID: 34480075
    [Abstract] [Full Text] [Related]

  • 12. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
    Al Therwani S, Malmberg MES, Rosenbaek JB, Bech JN, Pedersen EB.
    BMC Nephrol; 2017 Aug 15; 18(1):268. PubMed ID: 28810844
    [Abstract] [Full Text] [Related]

  • 13. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.
    Kidney Int; 2011 Aug 15; 80(3):295-301. PubMed ID: 21544064
    [Abstract] [Full Text] [Related]

  • 14. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O, TEMPO 3:4 Investigators.
    Kidney Int; 2019 Jul 15; 96(1):159-169. PubMed ID: 30898339
    [Abstract] [Full Text] [Related]

  • 15. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E, Rodas L, Blasco M, Molina A, Quintana L.
    Drugs Today (Barc); 2018 Sep 15; 54(9):519-533. PubMed ID: 30303493
    [Abstract] [Full Text] [Related]

  • 16. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M, Hirawa N, Sumida K, Kagimoto M, Ehara Y, Okuyama Y, Fujita M, Fujiwara A, Kobayashi M, Kobayashi Y, Yamamoto Y, Saka S, Yatsu K, Fujikawa T, Toya Y, Yasuda G, Tamura K, Umemura S.
    Clin Exp Nephrol; 2017 Oct 15; 21(5):858-865. PubMed ID: 28190113
    [Abstract] [Full Text] [Related]

  • 17. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients.
    Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Shiga T, Hatano M, Yao A, Kyo S, Komuro I.
    Circ J; 2013 Oct 15; 77(5):1208-13. PubMed ID: 23318562
    [Abstract] [Full Text] [Related]

  • 18. Validation of Surrogates of Urine Osmolality in Population Studies.
    Youhanna S, Bankir L, Jungers P, Porteous D, Polasek O, Bochud M, Hayward C, Devuyst O.
    Am J Nephrol; 2017 Oct 15; 46(1):26-36. PubMed ID: 28586769
    [Abstract] [Full Text] [Related]

  • 19. Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers?
    Gross P, Schirutschke H, Paliege A.
    Nephrol Dial Transplant; 2019 Jan 01; 34(1):35-37. PubMed ID: 30312449
    [Abstract] [Full Text] [Related]

  • 20. Analytical goals for quantitative urine analysis.
    Shephard MD, Penberthy LA, Fraser CG.
    Pathology; 1981 Jul 01; 13(3):543-6. PubMed ID: 7301420
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.